\n<\/p>\n
In <\/strong>SAM et al. v. Kennedy (1:26-cv-01081)<\/strong><\/i>, the Court Weighs Whether CMS Overstepped Its Authority by allowing Hemp, Marijuana Cannabinoid Access Without FDA Approval.<\/strong><\/p>\n Duane Boise, CEO of MMJ International Holdings stated “By holding the motion under advisement rather than ruling immediately, the court signaled that the issue is both complex and consequential.”<\/strong><\/p>\n<\/p><\/div>\n The case, A Decision With National Implications<\/strong><\/p>\n At issue is not just one program-but a fundamental question:<\/p>\n Can federal healthcare systems introduce therapeutic products before they are proven safe and effective?<\/strong><\/a><\/p>\n For decades, the answer has been no.<\/p>\n The established federal sequence has been:<\/p>\n clinical research – clinical trials – FDA approval – patient access<\/p>\n The CMS Beneficiary Engagement Incentive (BEI) model reverses that order.<\/p>\n The Court Signals the Stakes<\/strong><\/p>\n By holding the motion under advisement rather than ruling immediately, the court signaled that the issue is both complex and consequential.<\/p>\n Legal analysts note that such decisions typically involve:<\/p>\n statutory authority limits<\/p>\n<\/li>\n separation between CMS and FDA roles<\/p>\n<\/li>\n the evidentiary threshold for patient safety<\/p>\n<\/li>\n<\/ul>\n Why This Matters for Patients<\/strong><\/p>\n The debate is not abstract.<\/p>\n It affects real people-particularly seniors relying on Medicare.<\/p>\n Key concerns raised in the litigation include:<\/p>\n lack of FDA approval for cannabinoid products being furnished<\/p>\n<\/li>\n absence of standardized dosing and manufacturing controls<\/p>\n<\/li>\n limited long-term safety data<\/p>\n<\/li>\n potential exposure of vulnerable populations to unvalidated therapies<\/p>\n<\/li>\n<\/ul>\n The Impact on Scientific Development<\/strong><\/p>\n Clinical-stage developers pursuing cannabinoid therapies through FDA pathways warn that reimbursement-first models may undermine the incentive to conduct rigorous trials.<\/p>\n Companies investing in:<\/p>\n Investigational New Drug (IND) programs<\/p>\n<\/li>\n stability and formulation testing<\/p>\n<\/li>\n safety and toxicology studies<\/p>\n<\/li>\n<\/ul>\n face a growing concern:<\/p>\n If access comes before evidence, the incentive to generate evidence weakens.<\/strong><\/p>\n CMS Authority Under Scrutiny<\/strong><\/p>\n The Centers for Medicare & Medicaid Services Innovation Center has broad authority to test payment and care delivery models.<\/p>\n However, the lawsuit argues that this authority does not extend to redefining what qualifies as a therapeutic product eligible for Medicare-connected use.<\/p>\n That role has historically belonged to the FDA.<\/p>\n What Happens Next<\/strong><\/p>\n The court is expected to issue a written ruling in the coming days, determining whether the CMS program:<\/p>\n In Closing<\/strong><\/p>\n The outcome of this case will help define the future of cannabinoid medicine in the United States.<\/p>\n At its core, the issue is simple:<\/p>\n Should medicine follow science-<\/strong> Madison Hisey
\n WASHINGTON, May 8, 2026 (Newswire.com)
\n –
\n <\/strong>The future of federal cannabinoid policy now sits with the court after Judge Trevor N. McFadden took under advisement an emergency motion to halt the Centers for Medicare & Medicaid Services’ (CMS) cannabinoid access program.<\/strong><\/a><\/p>\n
Smart Approaches to Marijuana (SAM), et al. v. Robert F. Kennedy Jr., et al.<\/strong>
Case No. 1:26-cv-01081 (D.D.C.)<\/strong>,
challenges whether CMS exceeded its authority by allowing provider mediated furnishing of certain cannabinoid products to Medicare beneficiaries without approval from the U.S. Food and Drug Administration.<\/a><\/p>\n\n
\n
\n
or should access come first, and evidence later?<\/strong><\/p>\n
MHisey@mmjih.com<\/a>
203-231-8583<\/p>\n